ERBB2 and breast carcinoma: Ado-trastuzumab emtansine (Kadcyla®) and Trastuzumab deruxtecan (Enhertu®), both targeting HER2, are ADCs widely used in the treatment of HER2+ metastatic or locally advanced breast cancer.